Although hepatitis C virus (HCV) is a leading cause of morbidity and mortality worldwide, the role of viral cytopathic effects remains unclear. To study the biosynthesis of HCV structural proteins and their pathogenic role, transgenic mice expressing type 1b HCV structural proteins (core, E1 and E2) have been constructed using liver-specific promoters. Expression of HCV transgenes was detected in several lines by Northern blot, HCV-specific reverse transcriptase-polymerase chain reaction (RT-PCR), and Western immunoblotting. Immunohistochemical analysis revealed a predominately cytoplasmic presence of core protein with occasional nuclear staining, and both cytoplasmic and membrane expression of the E2 protein in the transgenic livers. At six months of age, the livers of all transgenic lineages remain histologically normal. Therefore HCV structural proteins are not directly cytopathic in this animal model. Our laboratory are also generating transgenic mice with full-length HCV genome and are developing a system for inducible expression of HCV transgenes using the tetracycline-inducible system. These animal will provide a useful animal model not only to address issues of immunopathogenesis and cytopathic potential of HCV gene products but also to study HCV replication in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Intramural Research (Z01)
Project #
1Z01DK054504-01
Application #
6162032
Study Section
Special Emphasis Panel (DDB)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Carpentier, Arnaud; Nimgaonkar, Ila; Chu, Virginia et al. (2016) Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable for high-throughput screen. Stem Cell Res 16:640-50
Carpentier, Arnaud; Tesfaye, Abeba; Chu, Virginia et al. (2014) Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model. J Clin Invest 124:4953-64
Ghany, Marc G; Liang, T Jake (2014) Building bridges and providing transparency to the hepatitis C virus drug approval process. Gastroenterology 147:1201-3
Clegg, Deborah J; Gotoh, Koro; Kemp, Christopher et al. (2011) Consumption of a high-fat diet induces central insulin resistance independent of adiposity. Physiol Behav 103:10-6
Rotman, Yaron; Liang, T Jake (2009) Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 83:7366-74
Modi, A A; Liang, T J (2008) Hepatitis C: a clinical review. Oral Dis 14:10-4
Chung, Raymond T; Gale Jr, Michael; Polyak, Stephen J et al. (2008) Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology 47:306-20
Kato, Takanobu; Matsumura, Takuya; Heller, Theo et al. (2007) Production of infectious hepatitis C virus of various genotypes in cell cultures. J Virol 81:4405-11
Lutchman, Glen; Danehower, Susan; Song, Byung-Cheol et al. (2007) Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 132:1757-66
Liang, T Jake (2007) Shortened therapy for hepatitis C virus genotype 2 or 3--is less more? N Engl J Med 357:176-8

Showing the most recent 10 out of 43 publications